Melanotan II is a synthetic peptide studied primarily for its effects on skin pigmentation, but it also appears to darken hair in a subset of users. Topical hair dyes work through entirely different chemistry, depositing or developing color molecules on the hair shaft. The comparison matters because one approach triggers endogenous melanin production while the other coats the hair externally. Neither method has been approved by regulatory agencies for cosmetic hair darkening, though both are used off-label.
This article examines the mechanisms, typical protocols reported in research and user logs, and the timeline of visible changes for each method. It also notes where clinical evidence exists and where it does not.
Why compare melanotan II and topical dyes
The two interventions occupy different positions on the spectrum of hair color modification. Topical dyes have decades of consumer use and safety data. Melanotan II has a narrower evidence base, mostly derived from tanning studies that recorded hair darkening as a secondary observation.
People consider melanotan II when they want a systemic effect that may darken both skin and hair simultaneously, or when they seek a change that does not require repeated topical application. Topical dyes remain the default for localized, predictable color change without systemic exposure. The choice hinges on tolerance for injection, desired permanence, and willingness to accept uncertain outcomes.
Melanotan II: mechanism and receptor activity
Melanotan II is an analog of alpha-melanocyte-stimulating hormone. It binds to melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases eumelanin synthesis, the brown-black pigment responsible for darker skin and hair.
In a 2000 study published in the Journal of Clinical Endocrinology & Metabolism, Dorr and colleagues administered melanotan II to healthy volunteers and observed dose-dependent skin tanning. Hair darkening was noted anecdotally in some participants but was not quantified. A 2009 review in Expert Opinion on Investigational Drugs by Hadley and Dorr summarized that melanotan II crosses into hair follicles and stimulates follicular melanocytes, though the degree of penetration varies by individual.
The peptide also binds MC4R, which mediates effects on appetite and sexual function. PT-141 (bremelanotide) is a derivative of melanotan II with reduced MC1R affinity and preferential MC4R activity, developed specifically for sexual dysfunction. PT-141 produces minimal tanning or hair darkening compared to melanotan II.
Melanotan II protocols reported in research and user communities
Clinical trials have used doses in the range of 0.16 to 0.25 milligrams per kilogram per day, administered subcutaneously. For a 70-kilogram adult, that translates to something like 11 to 17 milligrams daily. Most trials lasted two to four weeks.
Off-label protocols described in user forums typically start with a loading phase of 0.5 to 1 milligram per day for one to three weeks, followed by a maintenance dose of 0.25 to 0.5 milligrams once or twice weekly. These regimens are not validated by controlled trials and carry unknown risk profiles.
Hair darkening, when it occurs, is reported to begin after one to two weeks of daily dosing. The effect appears more pronounced in individuals with naturally brown or black hair who have experienced lightening due to age or sun exposure. People with very light blonde or red hair report minimal change, consistent with lower baseline MC1R activity in those phenotypes.
Timeline and before-after observations for melanotan II
Published case reports and user logs suggest the following approximate timeline. At one week, no visible hair color change is typically noted. At two weeks, some users report a subtle darkening of roots, particularly in areas with high hair density. At four weeks, the darkening may extend several centimeters along the hair shaft if dosing continues daily.
A 2012 case series in Dermatologic Therapy documented three individuals who used melanotan II for tanning and reported concurrent hair darkening. Photography showed a shift from medium brown to dark brown over a six-week period. The authors noted that hair color reverted toward baseline within three months of stopping the peptide.
The reversibility is consistent with the natural hair growth cycle. Melanin is deposited during the anagen phase, and once the peptide is withdrawn, new growth returns to the individual's genetically determined color. Existing darkened hair remains until it is cut or naturally shed.
Topical hair dyes: mechanisms of action
Topical dyes fall into three broad categories. Temporary dyes coat the hair surface with large color molecules that wash out after one shampoo. Semi-permanent dyes use smaller molecules that partially penetrate the cuticle and last through five to ten washes. Permanent dyes combine a developer (usually hydrogen peroxide) with dye precursors that undergo oxidation inside the hair shaft, forming larger colored molecules that resist washing.
Permanent dyes typically contain para-phenylenediamine or related aromatic amines. These molecules are small enough to enter the cortex, where they react with peroxide to form polymeric pigments. The process is well characterized in cosmetic chemistry literature, including a 2007 review in the International Journal of Cosmetic Science by Bouillon and Wilkinson.
Unlike melanotan II, topical dyes do not interact with melanocytes or alter endogenous pigment production. They add color externally, independent of the user's genetic or hormonal profile.
Topical dye protocols and application frequency
Permanent dyes are applied every four to six weeks to cover new root growth. The dye is mixed immediately before application and left on the hair for 20 to 45 minutes, depending on the formulation and desired intensity. Semi-permanent dyes are applied every two to four weeks. Temporary dyes are applied as needed, often daily or before specific events.
The timeline for visible results is immediate for all three types. Color develops fully during the application window. There is no lag period, and the result is predictable based on the starting hair color and the dye shade selected.
Before-after timeline for topical dyes
At time zero (application), the dye is distributed through the hair. At 30 minutes, oxidation is largely complete for permanent formulas, and the hair is rinsed. The final color is visible immediately after drying. For semi-permanent dyes, the color may deepen slightly over the first 24 hours as the molecules settle into the cuticle.
Fading begins with the first wash for semi-permanent dyes and occurs gradually over weeks. Permanent dyes fade more slowly, primarily due to UV exposure and oxidative stress. A 2015 study in the Journal of Cosmetic Dermatology by Draelos found that permanent dyes retained approximately 70 percent of their initial intensity after eight weeks of normal washing and sun exposure.
Head-to-head comparison: onset, durability, and predictability
Melanotan II requires one to two weeks before visible darkening appears, and the effect is limited to new hair growth during active dosing. Topical dyes produce immediate results that apply to the entire hair shaft. Melanotan II outcomes vary widely by individual, influenced by baseline melanocyte activity, receptor polymorphisms, and dosing consistency. Topical dyes offer highly predictable results, with color charts and strand tests to preview the outcome.
Durability also differs. Melanotan II-induced darkening persists only as long as the peptide is administered and reverses over months once stopped. Permanent topical dyes remain until the hair grows out or is cut, though they fade gradually. Semi-permanent dyes wash out in weeks.
Neither method has been studied in direct comparison trials. The evidence for melanotan II comes from tanning studies and off-label reports, while topical dyes have extensive consumer safety data and decades of use.
Where each approach is studied more extensively
Topical hair dyes dominate the published literature. The European Commission's Scientific Committee on Consumer Safety has evaluated hundreds of dye ingredients, and the U.S. FDA maintains a database of adverse event reports. Clinical studies on dye safety, allergenicity, and efficacy number in the thousands.
Melanotan II research is concentrated in dermatology and endocrinology, focused on tanning, photoprotection, and metabolic effects. A 2019 review in the British Journal of Dermatology by Brennan and colleagues summarized 15 clinical trials of melanotan II, none of which listed hair darkening as a primary endpoint. The peptide remains unapproved for any indication in most jurisdictions, and its use for cosmetic purposes is considered off-label.
PT-141, the MC4R-selective derivative, has been studied primarily for hypoactive sexual desire disorder. A 2016 phase III trial published in Obstetrics & Gynecology by Clayton and colleagues found no significant hair or skin pigmentation changes at therapeutic doses, consistent with its reduced MC1R activity.
Safety profiles and reported adverse events
Topical dyes are associated with contact dermatitis, particularly from para-phenylenediamine. Patch testing is recommended before first use. Systemic absorption is minimal, and serious adverse events are rare. A 2010 study in Contact Dermatitis by Søsted and colleagues found that approximately 4 percent of individuals tested positive for para-phenylenediamine allergy.
Melanotan II has been linked to nausea, facial flushing, spontaneous erections, and darkening of nevi. A 2014 case report in JAMA Dermatology described a user who developed multiple new melanocytic nevi after three months of melanotan II use. The long-term cancer risk is unknown. The peptide is not approved for cosmetic use, and regulatory agencies in Europe and Australia have issued warnings against its purchase from unregulated sources.
Relevance of other peptides in pigmentation research
Other peptides studied in skin and hair contexts include Matrixyl (palmitoyl pentapeptide), which is investigated for collagen synthesis rather than pigmentation. BPC-157 and TB-500 are examined for wound healing and tissue repair, with no direct evidence linking them to melanin production. Argireline (acetyl hexapeptide-8) is studied as a topical neuromodulator for wrinkle reduction and has no known melanocortin receptor activity.
None of these peptides overlap mechanistically with melanotan II in the context of hair darkening. They are mentioned here only to clarify that peptide-based interventions span diverse pathways, and effects on pigmentation are specific to melanocortin agonists.
Common questions
How long does melanotan II take to darken hair compared to topical dyes?
Melanotan II typically requires one to two weeks of daily subcutaneous dosing before users report visible darkening of hair roots. The effect extends along the hair shaft over subsequent weeks as new growth continues. Topical dyes produce immediate color change, with full results visible within 30 to 45 minutes of application. The difference in onset reflects the mechanisms: melanotan II stimulates melanocyte activity in hair follicles, a process that takes time, while topical dyes deposit or develop color molecules on the hair surface instantly. Neither timeline has been directly compared in controlled trials.
Is hair darkening from melanotan II permanent?
Hair darkening from melanotan II is not permanent. It persists only while the peptide is actively administered. Once dosing stops, new hair growth reverts to the individual's baseline color over the following weeks to months, depending on the hair growth cycle. Existing darkened hair remains until it is cut or naturally shed. A 2012 case series in Dermatologic Therapy documented this reversibility in three users, who returned to their original hair color within approximately three months of discontinuation. This contrasts with permanent topical dyes, which remain until the dyed hair grows out or is removed.
Which method is more predictable for achieving a specific hair color?
Topical dyes are far more predictable. Manufacturers provide color charts, and the outcome depends on the starting hair color and the dye shade selected. Strand tests allow users to preview results before full application. Melanotan II outcomes vary widely by individual, influenced by genetic factors such as MC1R polymorphisms, baseline melanocyte density, and dosing consistency. Some users report pronounced darkening, while others see minimal change. No standardized dosing protocol exists for cosmetic hair darkening, and the peptide is not approved for this use. Predictability favors topical dyes in all published comparisons.
Can melanotan II darken hair in people with blonde or red hair?
Melanotan II appears less effective in individuals with very light blonde or red hair. These phenotypes are often associated with loss-of-function variants in the MC1R gene, which reduce melanocyte response to melanocortin signaling. A 2000 study in the Journal of Clinical Endocrinology & Metabolism by Dorr and colleagues noted that tanning response to melanotan II was blunted in individuals with red hair and fair skin. User reports suggest similar limitations for hair darkening. People with brown or black hair who have experienced age-related or sun-induced lightening report more noticeable effects, likely because their melanocytes retain functional MC1R and can respond to the peptide.
What are the main safety concerns with melanotan II compared to topical dyes?
Melanotan II carries systemic risks including nausea, flushing, changes in libido, and potential effects on melanocytic nevi. A 2014 case report in JAMA Dermatology described new nevus formation in a user after three months of melanotan II. Long-term cancer risk is unknown, and the peptide is not approved for cosmetic use. Topical dyes are associated primarily with contact dermatitis, especially from para-phenylenediamine. Patch testing reduces this risk. Systemic absorption from topical dyes is minimal, and serious adverse events are rare. Regulatory oversight is far more established for topical dyes, with extensive safety databases maintained by agencies in Europe and the United States.
Do any clinical trials compare melanotan II and topical dyes for hair darkening?
No clinical trials have directly compared melanotan II and topical dyes for hair darkening. Melanotan II studies focus on skin tanning and photoprotection, with hair darkening recorded as an incidental observation. A 2019 review in the British Journal of Dermatology by Brennan and colleagues summarized 15 melanotan II trials, none of which listed hair color as a primary or secondary endpoint. Topical dye research centers on safety, allergenicity, and consumer satisfaction, with no comparisons to systemic melanocortin agonists. The lack of head-to-head data means that comparisons rely on separate evidence streams and user reports rather than controlled experimental design.
How does PT-141 differ from melanotan II in terms of hair darkening?
PT-141 (bremelanotide) is a derivative of melanotan II with preferential binding to MC4R and reduced affinity for MC1R. Because MC1R mediates melanin production in skin and hair, PT-141 produces minimal tanning or hair darkening. A 2016 phase III trial published in Obstetrics & Gynecology by Clayton and colleagues found no significant pigmentation changes at therapeutic doses used for hypoactive sexual desire disorder. Melanotan II retains strong MC1R activity and is associated with both tanning and hair darkening in users. The structural modification that created PT-141 was intended to isolate the sexual function effects while minimizing pigmentation, and clinical data support this differentiation.
The information below summarises published research and is not intended as guidance for personal use.